Isolated solitary recurrent skull metastasis in papillary thyroid carcinoma

Dukhabandhu Naik,1 Felix K Jebasingh,2 Krishna Prabhu,3 Nihal Thomas4

DESCRIPTION
A 38-year-old woman presented with history of painless expansible swelling in the right frontoparietal region since 2 years and rapidly increasing in size since the last 6 months. She was initially evaluated in another centre and was diagnosed as a meningioma. She had a history of total thyroidectomy and radioiodine ablation for a non-metastatic papillary carcinoma thyroid (PCT) in the year 2008. She was on a regular follow-up between 2009 and 2012 and during that period her serum thyroglobulin and whole-body iodine scan was normal. However, she was lost to follow-up but she had continued her suppressive doses of thyroxin.

Her T1-weighted MRI showed a lobulated expansile, intensely heterogeneously enhancing lesion arising from the right frontoparietal region (size 77×52×88 cm) (figure 1). The fluorodeoxyglucose-positron emission tomography (PET) CT scan showed a metabolically active expansile soft tissue lesion (standard uptake values, 64) with lytic area and bony spicules (figure 2). There is no uptake in the thyroid bed or any other region, thereby suggesting solitary skeletal metastases. Her serum thyroglobulin level was 2260 ng/mL, hence a final diagnosis of PCT with isolated solitary skeletal metastasis was considered. She was advised I-131 whole body scan (total body scan) 4 weeks after stopping thyroxine; however, she did not come back for follow-up.

Skeletal metastasis is seen in 1%–7% of patients with PCT at diagnosis.1 Isolated solitary metastatic skull recurrence is rare in post-treatment cases of PCT. PET scan or an I-131 whole body scan is helpful in detecting the extent of bone metastasis in differentiated thyroid carcinoma.2 Excision of a metastatic skull lesion followed by I-131 radioiodine and thyroxine replacement is the ideal line of treatment.3

Learning points
► Metastatic lesions should be considered in the differential diagnosis of an expansible solitary skull lesion in patients with a history of thyroid carcinoma.
► The delay in presentation is common among patients with differentiated thyroid carcinoma because of the asymptomatic nature of the metastatic lesion.
► Early diagnosis of a metastatic lesion has a significant impact on a decision-making in treatment and prognosis in patients with differentiated thyroid carcinoma.

Contributors DN and FKJ prepared the manuscript. KP was involved in the management of the patient. DN, FKJ, KP and NT edited and finalised the manuscript.

1Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India
2Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India
3Department of Neurosurgery, Christian Medical College, Vellore, Tamil Nadu, India
4Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India

Correspondence to
Dr Nihal Thomas, nihal_thomas@yahoo.com

Accepted 7 April 2018
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES